A new plaque psoriasis entrant must clear an 85% PASI 90 bar on dosing interval or route, not incremental clearance, while Stelara's 66% IRA cut and two biosimilar waves compress the price it can defend.
The moderate-to-severe plaque psoriasis market is no longer contested on PASI 75. Bimekizumab (Bimzelx) delivered PASI 90 in 85% of patients at week 16 in BE VIVID; risankizumab (Skyrizi) posted 75.3% and guselkumab (Tremfya) 73.3% against their respective comparators. That is the efficacy bar a new IL-17 or IL-23 entrant must clear, and clearing it is no longer sufficient on its own: risankizumab's q12w maintenance dosing, not its efficacy, is what made it the class volume leader, and deucravacitinib (Sotyktu) carved distinct space by being the first oral to beat apremilast rather than by beating the injectables. A new entrant's differentiation has to be dosing interval, route, or a comorbidity angle (psoriatic arthritis affects 19.7% of psoriasis patients), not marginal PASI improvement.
Whatever clinical lane a new agent chooses, it launches into a price architecture two forces are compressing simultaneously. Under the IRA, Medicare negotiated Stelara (ustekinumab) down 66% to $4,695 and Enbrel (etanercept) down 67% to $2,355, both effective January 2026, the first direct government price-setting on a psoriasis biologic. At the same time, adalimumab picked up 9-10 biosimilars in 2023 and ustekinumab biosimilars began launching in January 2025, eroding the legacy anchors from below. Branded strategy for the current IL-17/IL-23 leaders (not yet IRA-selected) is retreating toward mechanisms negotiation and biosimilars have not yet reached; a new entrant has to price and position against that retreat, not against today's list prices. ICER's 2018 assessment, which put cost-per-QALY at $131k-$188k across the class and recommended limiting step therapy, is the value precedent payers will apply.
The plaque psoriasis bar a new entrant must clear — clearance, dosing interval, and IRA/biosimilar exposure
| Drug (Brand / INN) | Mechanism | Key Trial Result | Dosing | IRA / Biosimilar Status |
|---|---|---|---|---|
| Bimzelx (bimekizumab) | Dual IL-17A/F mAb | BE VIVID: PASI 90 85% wk16 vs 50% ustekinumab | q4w after loading | Not yet IRA-selected; no biosimilar |
| Skyrizi (risankizumab) | IL-23p19 mAb | UltIMMa: PASI 90 75.3% wk16 vs 42% ustekinumab | q12w maintenance | Not yet IRA-selected; no biosimilar |
| Sotyktu (deucravacitinib) | Oral TYK2 inhibitor | POETYK PSO-1: PASI 75 58.4% vs 35.1% apremilast | Once-daily oral | Not yet IRA-selected; no biosimilar |
| Stelara (ustekinumab) | IL-12/23 mAb | Legacy incumbent, biosimilar-eroded | q12w | IRA IPAY 2026: -66% to $4,695; biosimilars from Jan 2025 |
Sources: BE VIVID (Lancet 2021, PMID 33549193); UltIMMa-1/2 (Lancet 2018, PMID 30097359); POETYK PSO-1 (JAAD 2022, PMID 35820547); CMS Medicare Drug Price Negotiation Program IPAY 2026 fact sheet / HHS ASPE; FDA biosimilar approvals; AJMC and Center for Biosimilars biosimilar-launch tracking; ICER 2018 targeted-immunomodulators for plaque psoriasis assessment.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The 85%/75.3%/73.3% PASI 90 benchmarks a new entrant must clear or exceed
- Why dosing interval (q12w) made risankizumab the volume leader despite lower clearance than bimekizumab
- Where an oral route (the Sotyktu precedent) or a psoriatic-arthritis label can substitute for incremental efficacy
Delivers
- The Stelara (-66%) and Enbrel (-67%) negotiated prices effective January 2026 and which mechanisms are not yet selected
- The 2023 adalimumab and 2025 ustekinumab biosimilar-uptake trajectories as a template for future erosion
- ICER's cost-per-QALY range ($131k-$188k) and its step-therapy-limitation recommendation
Delivers
- Sizing of the roughly one-in-five moderate-to-severe, systemic-eligible population within the 7.55M-adult base
- The psoriatic arthritis overlap (19.7%) that redirects a subset toward rheumatology co-management
- Try-two-fail step-edit prevalence at major commercial payers
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Why an 85% PASI 90 bar is now table stakes and dosing interval or route is the real differentiator
- The IRA-cut, biosimilar-eroded price anchor a new entrant is pricing against
- Bimekizumab, risankizumab and guselkumab's PASI 90 positioning and dosing-interval trade-offs
- Deucravacitinib's oral wedge against apremilast and the biosimilar-exposed legacy mechanisms
- Sizing the roughly one-in-five moderate-to-severe, systemic-eligible population within the 7.55M-adult base
- The 19.7% psoriatic arthritis overlap and its effect on mechanism choice
- The Stelara and Enbrel IRA negotiated prices effective January 2026 and which mechanisms remain unselected
- Try-two-fail step-edit prevalence and ICER's 2018 recommendation to limit it
- Every population, pricing, and trial figure sourced, confidence-rated and traceable
- Built to survive an internal challenge meeting
- Dermatology and rheumatology prescriber landscape and where new-entrant detailing should concentrate
- Specialty pharmacy distribution readiness for an injectable or oral entrant
- Open questions on dosing-interval positioning and step-edit sequencing to close before launch strategy is locked
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
This assessment synthesises three independently-verified research angles into one launch-readiness view: incumbent competitive positioning, target-population epidemiology, and anticipated payer posture. Every factual claim traces to a primary source: FDA approval records, peer-reviewed trial publications, and CMS/ICER documentation.
Psoriasis sources: FDA Drugs@FDA, BE VIVID/UltIMMa/POETYK PSO-1 primary publications, NHANES 2011-2014 epidemiology (PMID 34190957), CMS Medicare Drug Price Negotiation Program IPAY 2026 fact sheet, FDA biosimilar approval records, and the ICER 2018 targeted-immunomodulators for plaque psoriasis assessment.
- PASI 90/75 clearance figures verified against the primary BE VIVID, UltIMMa, and POETYK PSO-1 publications
- IRA negotiated prices for Stelara and Enbrel verified against the CMS IPAY 2026 fact sheet and HHS ASPE
- Adalimumab and ustekinumab biosimilar launch counts and dates verified against FDA and Center for Biosimilars records
- No figure carried from model memory; every parameter traceable to a named source in the assumption register
Frequently asked questions
Commission this assessment
AXLRx delivers plaque psoriasis launch-readiness assessments built for pharma and biotech commercial, access, and medical affairs teams preparing a pipeline asset. Custom assessment in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.